





碧云天生物技术/Beyotime Biotechnology 订货热线: 400-168-3301或800-8283301

订货e-mail: order@beyotime.com 技术咨询: info@beyotime.com 网址: http://www.beyotime.com


K-115 (ROCK抑制剂)

产品编号	产品名称	包装
SC6542-10mM	K-115 (ROCK抑制剂)	10mM×0.2ml
SC6542-5mg	K-115 (ROCK抑制剂)	5mg
SC6542-25mg	K-115 (ROCK抑制剂)	25mg

产品简介:

▶ 化学信息:

化学名	4-fluoro-5-[[(2S)-2-methyl-1,4-diazepan-1-	
	yl]sulfonyl]isoquinoline	
简称	K-115	
别名	K115 compound, Glanatec, Ripasudil	
中文名	N/A	
化学式	$C_{15}H_{18}FN_3O_2S$	
分子量	323.39	
CAS号	223645-67-8	
纯度	98%	
溶剂/溶解度	Water <1mg/ml; DMSO 4mg/ml; Ethanol <1mg/ml	
溶液配制	5mg加入1.55ml DMSO, 或每3.23mg加入1ml DMSO,	
	配制成10mM溶液。SC6542-10mM用DMSO配制。	



▶ 生物信息:

工物 [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
产品描述	K-115, an isoquinolinesulfonamide compound, is a highly selective and potent (IC50=31nM) Rho-kinase inhibitor; is in Phase II clinical development in patients with POAG or ocular hypertension.				
信号通路	Cell Cycle; DNA Damage				
靶点	ROCK				
IC50	31nM				
体外研究	K-115 had selective and potent inhibitory effects on ROCKs. In rabbits, topical instillation of K-115 significantly reduced IOP in a dose-dependent manner. Maximum IOP reduction was observed 1h after topical instillation, which was 8.55±1.09mmHg (mean±SE) from the baseline IOP at 0.5%. In monkeys, maximum IOP reduction was observed 2h after topical instillation, which was 4.36±0.32mmHg from the baseline IOP at 0.4%, and was significantly stronger than that of 0.005% latanoprost. Whole-head autoradiography showed that the radioactivity level was maximum at 15min after instillation of [(14)C]K-115 in the ipsilateral eye. NC-induced oxidative stress, including oxidation of lipids and production of ROS, was significantly attenuated by K-115. Furthermore, expression of the Nox gene family, especially Nox1, which is involved in the NC-induced ROS production pathway, was dramatically reduced by K-115.				
体内研究	N/A				
临床实验	N/A				
特征	N/A				

▶ 相关实验数据(此数据来自于公开文献,碧云天并不保证其有效性):

	酶活性检测实验		
· · · · · ·	方法	N/A	

	细胞实验
细胞系	N/A
浓度	N/A
处理时间	N/A
方法	N/A

	动物实验
动物模型	N/A
配制	N/A
剂量	N/A
给药方式	N/A

▶ 参考文献:

- 1. Tanihara H, et al. JAMA Ophthalmol. 2013 Oct, 131(10), 1288-95.
- 2. Isobe T, et al. Curr Eye Res. 2014 Aug, 39(8), 813-22.

包装清单:

产品编号	产品名称	包装
SC6542-10mM	K-115 (ROCK抑制剂)	10mM×0.2ml
SC6542-5mg	K-115 (ROCK抑制剂)	5mg
SC6542-25mg	K-115 (ROCK抑制剂)	25mg
_	说明书	1份

保存条件:

-20℃保存,至少一年有效。5mg和25mg包装也可以室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月有效。

注意事项:

- ▶ 本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
- ▶ 为了您的安全和健康,请穿实验服并戴一次性手套操作。

使用说明:

- 1. 收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒,以使液体或粉末充分沉淀至管底后再开盖使用。
- 2. 对于10mM溶液,可直接稀释使用。对于固体,请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
- 3. 具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其他相关文献,或者根据实验目的,以及所培养的特定细胞和组织,通过实验进行摸索和优化。
- 4. 不同实验动物依据体表面积的等效剂量转换表请参考如下网页: http://www.beyotime.com/support/animal-dose.htm

Version 2017.11.01